Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD

被引：0
|
作者：
Moens, A. [1 ,2 ]
Verstockt, B. [1 ,2 ]
Alsoud, D. [2 ]
Sabino, J. [1 ,2 ]
Ferrante, M. [1 ,2 ]
Vermeire, S. [1 ,2 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.433
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P309
引用
收藏
页码：S336 / S337
页数：4
相关论文
共 50 条
  • [1] Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD
    Moens, Annick
    Verstockt, Bram
    Alsoud, Dahham
    Sabino, Joao
    Ferrante, Marc
    Vermeire, Severine
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (08) : 1135 - 1142
  • [2] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [3] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [4] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Biemans, Vince B. C.
    Hoentjen, Frank
    Pierik, Marieke J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 92
  • [5] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY
    Sands, Bruce E.
    Schreiber, Stefan
    Lirio, Richard A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 93 - 94
  • [6] VEDOLIZUMAB SHOWS SUPERIOR EFFICACY VERSUS ADALIMUMAB: RESULTS OF VARSITY-THE FIRST HEAD-TO-HEAD STUDY OF BIOLOGIC THERAPY FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V.
    Danese, Silvio
    Colombel, Jean Frederic
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    GASTROENTEROLOGY, 2019, 156 (06) : S81 - S81
  • [7] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
    Yokomizo, Lauren
    Limketkai, Berkeley
    Park, K. T.
    BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):
  • [8] Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease
    Moens, A.
    Verstockt, B.
    Alsoud, D.
    Sabino, J.
    Ferrante, M.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I423 - I424
  • [9] Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease
    Moens, A.
    Verstockt, B.
    Alsoud, D.
    Sabino, J.
    Ferrante, M.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I423 - I424
  • [10] Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center
    Moens, Annick
    Alsoud, Dahham
    Verstockt, Bram
    Sabino, Joao
    Ferrante, Marc
    Vermeire, Severine
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (10) : 1015 - 1020
12345